Claims for Patent: 5,721,263

Summary for Patent: 5,721,263

Title:	Pharmaceutical composition for angiotensin II-mediated diseases
Abstract:	This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m-- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
Inventor(s):	Inada; Yoshiyuki (Kawanishi, JP), Kubo; Keiji (Riverside, CA)
Assignee:	Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:	08/351,011
Patent Claims:	1. A pharmaceutical composition, which comprises (.+-.)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -carboxylate or a pharmaceutically acceptable salt thereof in combination with manidipine hydrochloride. 2. A pharmaceutical composition, which comprises (.+-.)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -carboxylate or a pharmaceutically acceptable salt thereof in combination with hydrochlorothiazide. 3. A pharmaceutical composition, which comprises 2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl)biphenyl-4-yl]met hyl]-1H-benzimidazole-7-carboxylic acid or a pharmaceutically acceptable salt thereof in combination with manidipine hydrochloride. 4. A pharmaceutical composition, which comprises 2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl)biphenyl-4-yl]met hyl]-1H-benzimidazole-7-carboxylic acid or a pharmaceutically acceptable salt thereof in combination with hydrochiorothiazide. 5. A method for the treatment of hypertension in a mammal in need thereof, which comprises administering to said mammal an effective amount of (.+-.)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -carboxylate or a pharmaceutically acceptable salt thereof in combination with an effective amount of manidipine hydrochloride. 6. A method for the treatment of hypertension in a mammal in need thereof which comprises administering to said mammal an effective amount of (.+-.)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -caxboxylate or a pharmaceutically acceptable salt thereof in combination with an effective amount of hydrochlorothiazide. 7. A method for the treatment of hypertension in a mammal in need thereof which comprises administering to said mammal an effective amount of 2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl)biphenyl-4-yl]met hyl]-1H-benzimidazole-7-carboxylic acid or a pharmaceutically acceptable salt thereof in combination with an effective amount of manidipine hydrochloride. 8. A method for the treatment of hypertension in a mammal in need thereof which comprises administering to said mammal an effective amount of 2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl)biphenyl-4-yl]met hyl]-1H-benzimidazole-7-carboxylic acid or a pharmaceutically acceptable salt thereof in combination with an effective amount of hydrochlorothiazide.